How FDA's Proposed GRAS Transparency Rule Impacts Supplement Brands
By Jake, founder · Published · Source dated
FDA's proposed GRAS transparency rule seeks to enhance accountability and visibility. Supplement brands should review their GRAS determinations and consider engaging through industry groups.
What Changed?
The FDA has proposed a new rule aimed at strengthening the Generally Recognized as Safe (GRAS) framework. This move focuses on enhancing transparency and ensuring the FDA has better visibility into ingredients entering the food supply. The proposed rule is designed to make companies more accountable for their self-GRAS reviews while maintaining the pathway for innovation.
Who Does It Apply To?
This proposed rule primarily affects companies that utilize the self-GRAS pathway for affirming the safety of new ingredients. For Compliant Always, which relies on contract manufacturers and sells on Amazon, it means paying closer attention to the GRAS determinations made for the ingredients in your products. While the rule does not directly regulate Compliant Always, it impacts the manufacturers and suppliers Compliant Always works with.
What Does It Not Say?
The proposed rule does not specify detailed requirements for how companies should conduct their self-GRAS reviews. It also does not address the elimination of the self-GRAS pathway. Instead, it emphasizes making companies more accountable for these reviews and ensuring the FDA is aware of new ingredients entering the food supply. The rule does not mention specific timelines or deadlines for implementation.
Timelines and Dates
As of the publication date of the source text (August 11, 2026), there are no specific timelines or deadlines mentioned for the implementation of the proposed rule. The FDA has announced the proposal, and the next steps likely involve a period for public comment and further revisions before finalization. Compliant Always should stay informed about updates and potential timelines as they develop.
What Should Compliant Always Do Now?
Compliant Always should review its current GRAS determinations to ensure they align with the principles of accountability and transparency outlined in the proposed rule. Consider engaging with industry associations like CRN, which can provide guidance and support during this transition. A sensible step is to communicate with your contract manufacturers to understand how they plan to adapt to the new requirements.
Impact on Document Reviewers
Document reviewers may start looking for evidence of enhanced accountability and transparency in GRAS determinations. They might expect to see more detailed records of the self-GRAS review process and clearer communication with the FDA regarding new ingredients. However, the proposed rule does not mandate specific changes to the format or content of these documents.
Frequently asked questions
- Does the proposed rule eliminate the self-GRAS pathway?
- No, the proposed rule does not eliminate the self-GRAS pathway. It aims to make companies more accountable for their self-GRAS reviews and ensure FDA visibility.
- What is CRN's stance on the proposed rule?
- CRN supports the proposed rule for enhancing transparency and accountability but opposes eliminating the self-GRAS pathway, which could hinder innovation.
- Will the rule affect Compliant Always directly?
- The rule primarily affects manufacturers and suppliers. However, Compliant Always should review its GRAS determinations and engage through industry groups.
- Are there specific timelines for implementation?
- No specific timelines are mentioned. Stay informed about updates and potential deadlines as they develop.
Related guides
Sources
- Industry press — CRN Welcomes FDA Focus on Strengthening GRAS Transparency, Calls for National Uniformity accessed 2026-09-06
Written from the source text above and checked against it before publishing: every date, figure and section cited appears in the source. Information, not legal advice.